Womaness BBB and Consumer Complaint Trends: An Independent Review

What Is Womaness and Who Is It For?

Womaness markets itself as a "modern menopause" brand aimed at women in perimenopause and post-menopause. Founded in 2021, it sells a range of products including vaginal moisturizers, libido supplements, sleep aids, hot flash support formulas, and skin-care items through its own website and major retail partners including Target and CVS. The brand positions itself around the premise that menopause is a life stage to be managed openly rather than endured in silence.

The Life Stages Womaness Targets

The brand's core audience is women between roughly 40 and 60, the window that typically captures late perimenopause and the first decade after the final menstrual period. The Menopause Society defines perimenopause as the transitional period preceding menopause, often beginning in the mid-40s, during which estrogen fluctuates erratically and symptoms such as vasomotor flushes, sleep disruption, and genitourinary changes begin. Products aimed at this population occupy a specific regulatory grey zone: they are sold as supplements or cosmetics, not drugs, yet they are purchased by women seeking relief from genuine medical symptoms.

What Womaness Sells

The product lineup includes:

• Supplement capsules: hot flash support, libido blends, sleep formulas
• Topical products: vaginal moisturizers, lubricants, and vulvar soothing creams
• Personal care: cleansers, wipes, and skin-support serums

Retail price points range from roughly $18 for single-use products to $45 and above for supplement bundles. Subscription options are available and have been a source of complaints (detailed below).

Womaness BBB Rating and Complaint History

Evaluating a consumer wellness brand requires looking past marketing copy and examining what actual customers report to third-party bodies. The Better Business Bureau (BBB) is one of the most accessible public records for this.

Current BBB Accreditation Status

As of January 2025, Womaness holds BBB accreditation. BBB accreditation means a business has agreed to the organization's standards for trust, including making a good-faith effort to resolve consumer disputes. Accreditation does not equal government endorsement and does not mean the products are clinically validated. The BBB's own language states that accreditation is based on business practices, not product efficacy.

Complaint Volume and Patterns

Consumer complaints filed with the BBB against Womaness cluster around several recurring themes:

1. Subscription auto-renewal: Customers report being enrolled in recurring shipments without clear consent or experiencing difficulty canceling.
2. Shipping and delivery delays: Reports of extended wait times with inadequate customer-service follow-up.
3. Refund disputes: Disagreements about eligibility for returns after receiving products, particularly opened supplements.
4. Product efficacy dissatisfaction: While not a BBB-actionable category per se, reviews note that relief from hot flashes or sleep disruption did not match advertised expectations.

This complaint profile is not unique to Womaness. It mirrors patterns seen across the D2C supplement industry broadly, where the FTC has repeatedly noted that negative-option and auto-ship billing models generate disproportionate consumer harm.

How to Interpret the BBB File

A BBB file is a useful starting point, not a final verdict. The BBB does not verify product claims, test ingredients, or have regulatory authority. For genuine safety signals you need to look at FDA databases, published adverse event reports, and peer-reviewed literature on the ingredients themselves.

Is Womaness Legit? Regulatory and Safety Framework

"Legit" means different things depending on what you are asking. Is it a real company that ships products? Yes. Does it make FDA-approved drug claims? No, and it would be violating federal law if it did. Are its ingredient claims backed by evidence? That varies by product.

FDA Regulatory Status

Womaness products are sold as dietary supplements or cosmetics in the United States. Under the Dietary Supplement Health and Education Act of 1994 (DSHEA), the FDA does not evaluate or approve supplements for efficacy before they reach shelves. Manufacturers are responsible for ensuring safety, and the FDA acts primarily after a problem is reported. This means a product can be sold legally while having limited or no clinical evidence for its stated purpose.

The FDA's current dietary supplement oversight framework requires that labels not make disease claims but permits structure/function claims such as "supports hormonal balance." Womaness stays within this lane, which is legal but can be misleading to women who interpret these phrases as medically meaningful.

LegitScript and Third-Party Verification

LegitScript, a compliance certification body used by payment processors and advertisers, verifies that online pharmacies and health merchants meet legal standards. LegitScript certification status for Womaness should be checked directly at legitscript.com, as status can change. As of this writing, Womaness does not appear to hold LegitScript pharmacy certification, which is expected given it does not sell prescription drugs.

State Attorney General and Consumer Protection Records

No state attorney general enforcement actions against Womaness were found in publicly accessible records as of January 2025. This absence is mildly reassuring but not conclusive; many consumer harms in the supplement space are never formally litigated.

The Evidence Behind Womaness Ingredients

Because Womaness products do not require FDA efficacy review, understanding the science behind their key ingredients falls on the consumer. This section applies evidence grading to the most prominent compounds in the Womaness lineup.

Hot Flash Support Formulas

The flagship hot flash supplement contains ingredients commonly seen in menopause OTC products, including:

Black cohosh (Actaea racemosa): This is the most studied non-hormonal botanical for vasomotor symptoms. A 2012 Cochrane review of 16 randomized controlled trials found that black cohosh may reduce the frequency of hot flashes by a modest degree compared with placebo, though effect sizes were inconsistent. The North American Menopause Society (now The Menopause Society) notes that black cohosh is one of the few botanicals with a reasonable evidence base, though it is not equivalent in efficacy to hormone therapy. The Menopause Society's 2023 position statement on non-hormonal therapies gives low-to-moderate certainty evidence for black cohosh.

Phytoestrogens (soy isoflavones, red clover): Evidence for these is modest. A 2007 meta-analysis published in Maturitas found soy isoflavones reduced hot flash frequency by approximately 20% compared with placebo, a statistically significant but clinically modest effect. Red clover isoflavones showed similar findings in a 2007 trial published in Gynecological Endocrinology.

Ashwagandha (Withania somnifera): Often included in "stress and menopause" blends. A 2021 randomized controlled trial in Medicine found that 300 mg twice daily of ashwagandha root extract improved self-reported menopause symptom scores compared with placebo over 8 weeks, though the sample size was small (n=100) and the trial was industry-funded.

Vaginal Moisturizers and Lubricants

Genitourinary syndrome of menopause (GSM) affects an estimated 27 to 84 percent of postmenopausal women depending on the definition used, making this one of the highest-prevalence unmet needs in menopause care. Womaness sells non-hormonal vaginal moisturizers, which are appropriate OTC options for mild GSM symptoms. ACOG Practice Bulletin No. 141 recommends vaginal lubricants and moisturizers as first-line options for women with mild GSM or who prefer non-hormonal management.

These products are not a substitute for prescription vaginal estrogen in women with moderate to severe GSM. Women with significant symptoms should discuss low-dose vaginal estrogen or ospemifene with a clinician.

Sleep and Mood Formulas

Common ingredients include melatonin, L-theanine, and magnesium glycinate. The evidence for melatonin in menopause-related sleep disruption is limited but present. A 2014 randomized trial in Maturitas found that 3 mg melatonin nightly improved sleep quality scores in perimenopausal women over 6 months. Magnesium's role in sleep is supported by a 2012 randomized trial in the Journal of Research in Medical Sciences, though again the evidence base is not as strong as for prescription options.

Women's Physiology: Why Menopause Products Are Not One-Size-Fits-All

Women's responses to supplements depend substantially on hormonal status, which changes across the menopausal transition. In perimenopause, estrogen levels fluctuate rather than decline linearly, which means symptoms vary week to week and product effects may be harder to attribute. Research published in the journal Menopause confirms that estradiol variability in perimenopause is high, complicating any OTC intervention's signal.

Post-menopause, estrogen is consistently low. Phytoestrogens that act via estrogen receptors may theoretically have different effects depending on whether a woman's receptors are estrogen-replete or estrogen-starved, a pharmacodynamic nuance that has not been systematically studied in most supplement trials.

PCOS and Younger Women

Some women in their 30s or early 40s with polycystic ovary syndrome (PCOS) experience early menopause-like symptoms including hot flashes and sleep disruption due to hormonal dysregulation. PCOS affects approximately 6 to 12 percent of reproductive-age women in the United States. Womaness products are not positioned for PCOS specifically, and women in this group should seek care from a reproductive endocrinologist rather than relying on menopause OTC products.

Female-Specific Evidence Gaps

The supplement trials cited above share a common limitation: most enrolled postmenopausal women of a narrow age range, typically 45 to 60, and most were predominantly white. Black women, who on average enter menopause earlier and report more severe vasomotor symptoms, are underrepresented in menopause supplement trials. Women with surgically induced menopause, whose estrogen decline is abrupt rather than gradual, are also rarely studied in OTC supplement research.

Pregnancy, Lactation, and Contraception Considerations

Womaness products are marketed to perimenopausal and postmenopausal women, but perimenopause does not equal infertility. Ovulation can occur irregularly for years before the final menstrual period, and unintended pregnancy rates in women aged 40 to 44 remain non-trivial.

Black cohosh in pregnancy: Black cohosh is contraindicated in pregnancy. It has been associated with uterine stimulation and possible teratogenic effects in animal models. The American Herbalists Guild and multiple pharmacopoeia references list it as contraindicated during pregnancy. If you are perimenopausal and using black cohosh but have not confirmed menopause (12 consecutive months without a period), use reliable contraception.

Phytoestrogens in pregnancy: Soy isoflavones have weak estrogenic activity. Safety data in pregnancy is insufficient. Avoidance during pregnancy is generally advised based on the precautionary principle.

Ashwagandha in pregnancy: Ashwagandha is traditionally classified as an abortifacient in Ayurvedic medicine. A 2020 review in Nutrients cautions against its use in pregnancy due to animal data suggesting adverse fetal effects. Avoid during pregnancy and while trying to conceive.

Melatonin in pregnancy: Safety data for supplemental melatonin during pregnancy in humans is limited. The NIH Office of Dietary Supplements notes that evidence is insufficient to recommend melatonin during pregnancy or breastfeeding.

Lactation: None of the above ingredients have adequate human lactation data to be considered safe during breastfeeding. Women who are postpartum and breastfeeding should avoid these products and consult their obstetric provider.

Bottom line: If you are perimenopausal and not certain you are post-fertile, confirm your contraception status with a clinician before starting any of these products. Menopause is confirmed only after 12 consecutive months without menstruation.

Who Womaness Is Right For, and Who Should Look Elsewhere

Likely Appropriate Candidates

• Post-menopausal women with mild-to-moderate vasomotor symptoms who prefer non-hormonal options after a shared decision-making conversation with their clinician
• Women who are not candidates for hormone therapy (e.g., certain breast cancer survivors, though even this group should discuss with their oncologist) and want OTC options with some evidence base
• Women seeking non-hormonal vaginal moisturizers for mild GSM symptoms

Women Who Should Seek Clinical Care Instead

• Women with moderate to severe hot flashes: The Menopause Society's 2023 hormone therapy position statement affirms that hormone therapy remains the most effective treatment for vasomotor symptoms in appropriate candidates
• Women with moderate to severe GSM: low-dose vaginal estrogen or ospemifene (Osphena) have far stronger evidence than any OTC topical
• Women with untreated depression or anxiety that is worsening in the menopausal transition: SSRIs, SNRIs, and gabapentinoids have evidence in this context; supplements do not
• Women whose "menopause symptoms" have not been clinically evaluated: thyroid dysfunction, for example, mimics perimenopause closely and affects up to 20 percent of women over 60

Consumer Complaint Red Flags: What to Watch Before You Buy

If you are considering Womaness, here are specific steps to protect yourself based on the complaint patterns documented above.

Before Subscribing

• Read the subscription terms on the product page, not just the landing page
• Screenshot the cancellation policy before completing checkout
• Use a credit card rather than a debit card; chargebacks are easier to dispute

If You Have a Problem

• File a complaint at bbb.org directly under the Womaness business profile
• Report billing issues to your state Attorney General's consumer protection office
• For deceptive advertising claims, file a report with the FTC at ReportFraud.ftc.gov
• FDA MedWatch (fda.gov/safety/medwatch) accepts reports of adverse effects from dietary supplements

How Womaness Compares on the Transparency Spectrum

Transparency in the supplement industry is not binary. The most transparent brands publish Certificates of Analysis (COA) from third-party testing labs, disclose full ingredient doses (no proprietary blends), and do not make implied disease claims. As of this review, Womaness does not prominently display third-party COAs on its website. This is a common gap in the D2C supplement space, not a unique failing, but it means you cannot independently verify that what is on the label matches what is in the capsule.

The NSF International and USP verification marks, which appear on products that have passed independent purity and potency testing, are not present on the Womaness products reviewed for this article. If third-party certification matters to you, brands that carry NSF Certified for Sport or USP Verified marks offer a higher baseline of accountability.

A Note on Complaint Trends Across the Menopause Supplement Industry

Womaness exists within a broader market that is growing rapidly. Global menopause supplement sales are projected to exceed $22 billion by 2028, driven by aging demographics and increasing openness about midlife women's health. This growth has attracted both genuine innovation and opportunistic marketing. Complaint patterns at the BBB for menopause brands broadly mirror those seen at Womaness: subscription traps, inflated efficacy claims, and slow refund processing. The Womaness complaint profile is not dramatically worse than industry peers, but it is also not better.

Women deserve honest information about what these products can and cannot do. A vaginal moisturizer may genuinely improve daily comfort. A hot flash supplement may take the edge off mild flushing for some women. Neither replaces the clinical care that many perimenopausal and postmenopausal women genuinely need.